Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tipifarnib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tipifarnib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tipifarnib. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tipifarnib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Quinisocaine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Tipifarnib. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Tipifarnib is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Tipifarnib is combined with Etrasimod. |